Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GW003 in Breast Cancer Patients with Chemotherapy-Induced Neutropenia
NCT02725606Phase 1Unknown
- Sponsor
- Jiangsu T-mab Biopharma Co., Ltd.
- Start
- Mar 2016
- Primary completion
- Sep 2017
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rHSA-GCSF in chemotherapy-induced neutropenia (CIN) (4 arms), sponsored by Jiangsu T-mab Biopharma Co., Ltd. Primary endpoint: Frequency of adverse events and serious adverse events at 21 days. Status: unknown.
02
Drugs
rHSA-GCSF
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT02725606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02725606.